CeriBell, Inc (CBLL) AI Stock Analysis

CeriBell, Inc. operates as a medical technology company in the United States. Founded in 2014 and headquartered in Sunnyvale, California, the company was formerly known as Brain Stethoscope, Inc. before changing its name in August 2015. It develops the Ceribell System, a novel point-of-care EEG platform designed to address unmet needs for patients in acute care settings. Its product portfolio includes disposable, flexible headbands and headcaps, alongside a pocket-sized, rechargeable battery-operated recorder that captures and wirelessly transmits EEG signals. The company also provides Clarity, an AI-powered seizure detection algorithm, and an EEG portal enabling real-time remote data access.

CeriBell grew annual revenue from $25.9M in FY2022 to $45.2M in FY2023, $65.4M in FY2024, and $89.1M in FY2025, generating a 3-year revenue CAGR of 50.9%. Revenue growth was 74.5% in FY2023, 44.7% in FY2024, and 36.1% in FY2025. Gross margin expanded continuously over this period, rising from 82.9% in FY2022 to 87.9% in FY2025. Operating margin improved from -139.0% in FY2022 to -65.6% in FY2025, though annual net losses widened from -$37.2M to -$53.4M. For the latest quarter ended June 30, 2026, quarterly revenue increased 32.5% year-over-year, bringing trailing twelve-month revenue to $102.0M with an operating margin of -71.1%.

As of June 30, 2026, CeriBell held $129.3M in cash and short-term investments against $21.9M in total debt, resulting in a net cash position of $107.4M. The company maintains solid liquidity with a current ratio of 9.18 and a debt-to-equity ratio of 0.17 on $128.3M of shareholders' equity. Operating cash flow in FY2025 was -$40.8M, and free cash flow was -$41.6M after capital expenditures of $767,000. CeriBell does not pay dividends or repurchase shares as it funds ongoing commercialization and research operations.

At a share price of $25.04, CeriBell trades at a market capitalization of $961.0M and an enterprise value of $799.2M. The stock trades at a price-to-sales multiple of 9.4x and an enterprise value-to-revenue multiple of 7.8x, both above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio stands at 7.1x. Over the past year, CeriBell shares returned 92.8%, outperforming the S&P 500 benchmark return of 16.8%. The stock trades 21.9% above its 200-day moving average.

Wall Street coverage includes 7 Strong Buy ratings, 1 Buy rating, and zero Hold or Sell recommendations. The mean price target is $28.57, representing an upside of 14.1% from the last closing price of $25.04. Consensus estimates project FY2026 revenue of $115.5M and an EPS of -$1.96. For FY2027, five analysts expect revenue to grow 27.4% to $147.1M with EPS improving to -$1.61. CeriBell has exceeded earnings expectations in 3 of the last 4 quarters, with its next earnings report scheduled for November 3, 2026.

This page is an AI-written research summary of CeriBell, Inc (CBLL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CBLL income statement, CBLL balance sheet, CBLL key metrics, CBLL analyst forecast, CBLL chart. See the CBLL stock overview for the latest quote and news.